/FULC
FULC Stock - Fulcrum Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$12.28+0.99%
+$0.12 (+0.99%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+57.2%upside
Target: $19.30
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for FULC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$12.16 – $12.40
TARGET (TP)$19.30
STOP LOSS$11.30
RISK/REWARD1:7.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.17
52W High$15.74
52W Low$2.31
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $80.00M | $2.81M | $6.34M | $19.16M | $8.82M |
| Gross Profit | $16.61M | $2.81M | $-70,440,000 | $-50,538,000 | $-50,219,000 |
| Gross Margin | 20.8% | 100.0% | -1110.7% | -263.7% | -569.2% |
| Operating Income | $-21,897,000 | $-110,664,000 | $-112,561,000 | $-81,054,000 | $-71,611,000 |
| Net Income | $-9,725,000 | $-97,335,000 | $-109,871,000 | $-80,847,000 | $-70,819,000 |
| Net Margin | -12.2% | -3470.1% | -1732.4% | -421.9% | -802.7% |
| EPS | $-0.16 | $-1.59 | $-2.35 | $-2.22 | $-2.70 |
Company Overview
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
37%
Hold / Neutral
10
53%
Sell / Underperform
2
11%
Analyst Consensus🔴 Bearish
7 Bullish12 Neutral/Bearish
Price Targets
$9
Average Target
↓ 28.4% Downside
Now
$2
Low
$9
Average
$23
High
Based on 19 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Truist | Initiation | Buy | - |
| July 29th 2025 | H.C. Wainwright | Upgrade | Buy | $12← $4 |
| May 23rd 2025 | Leerink Partners | Upgrade | Outperform | $12 |
| May 15th 2025 | Cantor Fitzgerald | Upgrade | Overweight | $10 |
| September 13th 2024 | H.C. Wainwright | Downgrade | Neutral | $4← $17 |
| September 12th 2024 | RBC Capital Mkts | Downgrade | Sector Perform | $4← $15 |
| September 12th 2024 | Leerink Partners | Downgrade | Market Perform | $4 |
| September 12th 2024 | BofA Securities | Downgrade | Underperform | $2← $10 |
| September 12th 2024 | Stifel | Downgrade | Hold | - |
| September 12th 2024 | Cantor Fitzgerald | Downgrade | Neutral | - |
| September 9th 2024 | BofA Securities | Upgrade | Neutral | $10← $5 |
| May 20th 2024 | Cantor Fitzgerald | Initiation | Overweight | $23 |
| March 13th 2024 | RBC Capital Mkts | Initiation | Outperform | $14 |
| September 25th 2023 | Goldman | Initiation | Neutral | $5 |
| August 23rd 2023 | H.C. Wainwright | Upgrade | Buy | $14← $5 |
Earnings History & Surprises
FULCBeat Rate
76%
Last 17 quarters
Avg Surprise
+419.6%
EPS vs Estimate
Beats / Misses
13/4
Last 12 quarters
Latest EPS
$-0.31
Q4 2025
EPS Surprise History
Q1 24
+9.1%
$-0.40vs$-0.44
Q2 24
+2.3%
$-0.43vs$-0.44
Q3 24
+7060.5%
$0.87vs$0.01
Q4 24
+12.5%
$-0.35vs$-0.40
Q1 25
-10.7%
$-0.31vs$-0.28
Q2 25
+3.4%
$-0.28vs$-0.29
Q3 25
+3.4%
$-0.28vs$-0.29
Q4 25
-6.9%
$-0.31vs$-0.29
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $-0.32 | — | — | — |
Q4 2025 | Oct 29, 2025 | $-0.29 | $-0.31 | -6.9% | ✗ MISS |
Q3 2025 | Jul 29, 2025 | $-0.29 | $-0.28 | +3.4% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-0.29 | $-0.28 | +3.4% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $-0.28 | $-0.31 | -10.7% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.40 | $-0.35 | +12.5% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $0.01 | $0.87 | +7060.5% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.44 | $-0.43 | +2.3% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.44 | $-0.40 | +9.1% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.44 | $-0.39 | +11.4% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.44 | $-0.38 | +13.6% | ✓ BEAT |
Q2 2023 | Jun 23, 2023 | — | $-0.45 | — | — |
Q2 2023 | May 15, 2023 | $-0.47 | $-0.41 | +12.8% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.62 | $-0.50 | +19.4% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.66 | $-0.83 | -25.8% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.63 | $-0.64 | -1.6% | ✗ MISS |
Q1 2022 | Mar 3, 2022 | $-0.65 | $-0.58 | +10.8% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.64 | $-0.57 | +10.9% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.65 | $-0.60 | +7.7% | ✓ BEAT |
Latest News
Truist Securities Maintains Buy on Fulcrum Therapeutics, Raises Price Target to $18
📈 PositiveBenzinga•Dec 11, 2025, 05:47 PM
Fulcrum Therapeutics Prices $175M Public Offering of Common Stock And Pre‑Funded Warrants At $13.50
📉 NegativeBenzinga•Dec 10, 2025, 12:51 PM
B of A Securities Maintains Underperform on Fulcrum Therapeutics, Raises Price Target to $7
➖ NeutralBenzinga•Dec 9, 2025, 05:54 PM
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock
➖ NeutralSeeking Alpha•Dec 8, 2025, 09:09 PM
Fulcrum Therapeutics Announces Proposed $150M Public Offering Of Common Stock
➖ NeutralBenzinga•Dec 8, 2025, 09:03 PM
RBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $10
📈 PositiveBenzinga•Dec 8, 2025, 02:35 PM
Cantor Fitzgerald Maintains Overweight on Fulcrum Therapeutics, Raises Price Target to $24
📈 PositiveBenzinga•Dec 8, 2025, 02:27 PM
Piper Sandler Reiterates Overweight on Fulcrum Therapeutics, Raises Price Target to $23
📈 PositiveBenzinga•Dec 8, 2025, 02:09 PM
Fulcrum Therapeutics shares are trading higher after the company reported initial results from the 20 mg dose cohort of its Phase 1b PIONEER trial of Pociredir in sickle cell disease, showing a clear dose-response and robust fetal hemoglobin induction at week 6.
📈 PositiveBenzinga•Dec 8, 2025, 01:52 PM
HC Wainwright & Co. Maintains Buy on Fulcrum Therapeutics, Raises Price Target to $25
📈 PositiveBenzinga•Dec 8, 2025, 12:40 PM
Market-Moving News for December 8th
➖ NeutralBenzinga•Dec 8, 2025, 12:34 PM•Also:
Fulcrum Therapeutics Announced Saturday, Initial Results From 20 mg Dose Cohort Of The Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease; Clear Dose-response Observed, With Robust, Clinically Meaningful Fetal Hemoglobin Induction At Week 6 Timepoint
📈 PositiveBenzinga•Dec 7, 2025, 11:06 PM
Truist Securities Initiates Coverage On Fulcrum Therapeutics with Buy Rating, Announces Price Target of $14
📈 PositiveBenzinga•Nov 24, 2025, 05:56 PM
HC Wainwright & Co. Maintains Buy on Fulcrum Therapeutics, Raises Price Target to $18
📈 PositiveBenzinga•Nov 24, 2025, 12:57 PM
Fulcrum Therapeutics To Present New Data From The Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease (Scd) Will Be Presented At The 67th American Society Of Hematology Annual Meeting
📈 PositiveBenzinga•Nov 3, 2025, 09:48 PM
RBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $7
➖ NeutralBenzinga•Oct 30, 2025, 02:58 PM
Piper Sandler Reiterates Overweight on Fulcrum Therapeutics, Raises Price Target to $16
📈 PositiveBenzinga•Oct 30, 2025, 01:37 PM
Fulcrum Therapeutics Q3 EPS $(0.31) Misses $(0.29) Estimate; Cash $200.6M
📉 NegativeBenzinga•Oct 29, 2025, 11:02 AM
HC Wainwright & Co. Reiterates Buy on Fulcrum Therapeutics, Maintains $12 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 11:56 AM
Fulcrum Therapeutics to Present Preclinical Data on FTX-6274 for Advanced Prostate Cancer at ESMO 2025
➖ NeutralBenzinga•Oct 14, 2025, 11:11 AM
Frequently Asked Questions about FULC
What is FULC's current stock price?
Fulcrum Therapeutics, Inc. (FULC) is currently trading at $12.28 per share. The stock has moved +0.99% today.
What is the analyst price target for FULC?
The average analyst price target for FULC is $19.30, based on 1 analyst.
What sector is Fulcrum Therapeutics, Inc. in?
Fulcrum Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is FULC's market cap?
Fulcrum Therapeutics, Inc. has a market capitalization of $0.66 billion, making it a small-cap company.
Does FULC pay dividends?
No, Fulcrum Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADCT
ADC Therapeutics S.A.
$3.73
Mkt Cap: $0.4B
BCYC
Bicycle Therapeutics plc
$6.87
Mkt Cap: $0.5B
CMPX
Compass Therapeutics, Inc.
$4.99
Mkt Cap: $0.7B
LCTX
Lineage Cell Therapeutics, Inc.
$1.68
Mkt Cap: $0.4B
LXRX
Lexicon Pharmaceuticals, Inc.
$1.17
Mkt Cap: $0.4B
NGNE
Neurogene Inc.
$20.55
Mkt Cap: $0.3B
NMRA
Neumora Therapeutics, Inc. Common Stock
$1.75
Mkt Cap: $0.3B
OCGN
Ocugen, Inc.
$1.40
Mkt Cap: $0.4B
OMER
Omeros Corporation
$9.60
Mkt Cap: $0.7B
RAPT
RAPT Therapeutics, Inc.
$33.81
Mkt Cap: $0.6B
Explore stocks similar to FULC for comparison